AstraZeneca PLC and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

A Tale of Two Pharmaceutical Giants: SG&A Spending Trends

In the competitive world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a game-changer. Over the past decade, AstraZeneca PLC and Amneal Pharmaceuticals, Inc. have showcased contrasting SG&A spending patterns. AstraZeneca, a global leader, consistently allocated a significant portion of its budget to SG&A, peaking at approximately $18 billion in 2022, reflecting a 40% increase since 2014. This strategic investment underscores its commitment to maintaining a robust market presence and driving innovation.

Conversely, Amneal Pharmaceuticals, a key player in the generic drug market, exhibited a more conservative approach. Its SG&A expenses grew from $85 million in 2014 to $430 million in 2023, marking a fivefold increase. This growth highlights Amneal's strategic expansion efforts and its focus on scaling operations. These spending patterns reveal the diverse strategies employed by pharmaceutical companies to navigate the ever-evolving healthcare landscape.